Introduction
============

Renal failure or end-stage renal disease (ESRD) is a condition in which the kidneys cannot fulfill their functions of discharging metabolic wastes and of maintaining the fluid and electrolyte balance. It can be divided into two stages: acute and chronic.[@b1-ccid-7-313]

In the United States, about 12% (25 million) are estimated to have chronic kidney disease, whereas less than 0.2% have been treated by dialysis or transplantation.[@b2-ccid-7-313] The prevalence of chronic kidney disease is especially high in the elderly, affecting 40% of people over the age of 70 years.[@b3-ccid-7-313] Renal failure is a global public health problem, but the disease magnitude has been better characterized in developed countries.[@b4-ccid-7-313]

Dialysis is a treatment modality for ESRD, either hemodialysis (HD) or peritoneal dialysis.[@b5-ccid-7-313],[@b6-ccid-7-313] Patients on HD have a high prevalence of mucocutaneous changes because of several contributory factors, including uremia, metabolic disorders, dialysis, and side effects of immunosuppressive drugs.[@b7-ccid-7-313],[@b8-ccid-7-313] It is very difficult to judge whether any particular cutaneous manifestation is caused by either chronic renal failure or HD alone because many of them are associated with both of these situations.[@b9-ccid-7-313] Skin changes in dialysis patients have been categorized as specific skin manifestations (acquired perforating dermatosis, calcific uremic arteriolopathy, bullous diseases, and nephrogenic fibrosing dermopathy) and nonspecific skin manifestations (pruritus, xerosis, nail disorders, hair disorders, pigmentary changes, purpura, oral changes, pallor, and uremic frost).[@b10-ccid-7-313]

This study aimed to evaluate the prevalence and pattern of different mucocutaneous disorders among chronic HD patients in the HD units in Tanta University hospitals and to evaluate the relationship of these dermatological disorders with the duration of HD as well as different laboratory parameters in these patients.

Patients and methods
====================

A total of 93 adult patients attending the renal dialysis units in Tanta University hospitals for HD through a period of 6 months were included in this cross-sectional descriptive study, and a written informed consent was taken from those who agreed to participate. Patients with chronic skin diseases prior to onset of HD, patients receiving any treatment other than HD, and patients with other systemic diseases that may lead to dermatological changes were excluded.

Patients included in this study were subjected to complete history taking, thorough general and dermatological examination, and their lesions were photographed. Laboratory investigations in the form of complete blood counts, renal and hepatic functions tests, serum parathormone level, serum electrolytes, alkaline phosphatase, random blood sugar, and *Hepatitis C virus* antibodies were collected from the most recent data in the patients' files and were repeated when necessary.

Statistical analysis
====================

Statistical presentation and analysis was conducted using the mean, standard deviation, and chi-square test by the Statistics Package for Social Sciences, version 18. A *P*-value less than 0.05 was considered statistically significant.

Results
=======

The present study included 93 patients with ESRD on HD; 56 males (60.2%) and 37 females (39.8%), with a ratio of 1.5:1. Their ages ranged from 18--80 years with a mean of 50.23±14.10 years, and the duration of HD ranged from 0.5--180 months with a mean of 38.77±10.6 months.

The frequency distribution of different mucocutaneous, hair, and nail changes in chronic HD patients is shown in [Table 1](#t1-ccid-7-313){ref-type="table"} and [Figure 1](#f1-ccid-7-313){ref-type="fig"}. Regarding the prevalence of cutaneous changes in patients on HD, xerosis was the most common manifestation, detected in 86% of the patients, followed by hyperpigmentation in 56% (35.5% of HD patients had hyperpigmentation on exposed parts, while 20.4% had diffuse hyperpigmentation), pruritus in 51.6%, ecchymosis in 47.3%, and follicular hyperkeratosis in 48.4%.

Regarding hair changes, lusterless and brittle hair were most common, detected in 68.8% and 67.7% of patients, respectively, while 6.5% of the patients had diffuse hair loss.

For nail changes; half and half nails were the most common finding, detected in 76.3% of patients on HD, followed by onychomycosis in 30.1%, melanonychia in 24.7%, koilonychia in 23.7%, and subungal hyperkeratosis in 19.4%, while Mees' lines was the least common finding (9.75%).

Among mucous membrane changes, pallor of oral mucosa and yellow sclera were the most common findings, detected in 55.9% of HD patients. Xerostomia was present in 43.01% of patients, macroglossia in 37.6%, bleeding gums in 35.4%, and 10.7% of patients had aphthous stomatitis.

In the current study, there were statistically insignificant positive correlations between the presence of skin, hair, nail, and mucous membrane changes and the duration of HD ([Table 2](#t2-ccid-7-313){ref-type="table"}).

Correlations between skin manifestations in patients on HD and their laboratory investigations showed a statistically significant positive correlation between the presence of cutaneous changes (pruritus in particular) and serum parathormone level ([Table 3](#t3-ccid-7-313){ref-type="table"}). On the other hand, hair and nail changes showed statistically nonsignificant correlations with the laboratory findings of HD patients. Meanwhile, a statistically significant negative correlation was detected between the presence of mucous membrane changes and hemoglobin level ([Table 3](#t3-ccid-7-313){ref-type="table"}).

Discussion
==========

Skin problems are common and diverse in patients with ESRD, especially in those on HD, and they usually have no consistent association with age, sex, race, or precipitating disease for renal failure. They could predate the onset of dialysis or could be precipitated by it. [@b9-ccid-7-313],[@b11-ccid-7-313],[@b12-ccid-7-313]

In the present study, all HD patients showed one or more dermatological lesion, and these results were in agreement with results of Shah et al,[@b13-ccid-7-313] who reported that all patients of chronic kidney disease on maintenance HD in their study had at least one of the dermatological changes. In another study performed on 300 adult patients on HD, it was reported that cutaneous changes were present in 96% of them.[@b12-ccid-7-313] In the current study, there was no statistically significant relation between the duration of HD and the prevalence of dermatological changes in HD patients; these results were in agreement with those of Hajheydari et al.[@b8-ccid-7-313]

Xerosis was the most prevalent skin manifestation, was detected in 86% of HD patients in the current study, and the extremities were the most affected site, especially the lower limbs. Xerosis has been reported to be prevalent in 54% to 91% of patients on HD in various studies.[@b12-ccid-7-313],[@b14-ccid-7-313]--[@b18-ccid-7-313] Hajheydari et al[@b8-ccid-7-313] found xerosis in only 23% of HD patients. This difference might be attributed to environmental exposures and climatic factors; the present study was done in winter, which aggravates the condition of cutaneous dryness. Alteration of vitamin A metabolism, glycerol deficiency with skin dehydration, barrier dysfunction, chemically induced irritation, functional abnormalities of eccrine sweat glands, and high doses of diuretics may be responsible factors for xerosis in HD patients.[@b12-ccid-7-313],[@b13-ccid-7-313]

In the present study, 56% of patients had hyperpigmentation on sun-exposed parts of the body, or generalized all over the body. Udayakumar et al[@b14-ccid-7-313] reported this finding in 43% of their HD patients, while Mirza et al[@b12-ccid-7-313] reported that hyperpigmentation was found in 54.3% of their patients on HD. Diffuse hyperpigmentation could be attributed to increased levels of β-melanocyte stimulating hormone as a result of its inadequate excretion through kidney and dialysis.[@b18-ccid-7-313] Many HD patients show a yellowish tinge of dyspigmentation, which could be attributed to excess deposition of two major pigments, namely carotenoids and lipochromes, in the epidermis and subcutaneous tissue.[@b19-ccid-7-313] The use of high-flux HD or hemodiafiltration may increase the clearance of all the abovementioned substances, and thus improves the dyspigmentation.[@b20-ccid-7-313]

Another common cutaneous manifestation in this study was pruritus, with a prevalence rate of 51.6%. This condition may be attributed to dry skin and secondary hyperparathyroidism, which were very common in our patients. In the different published studies, the prevalence of pruritus ranged between 19% and 90%, and it has been reported that pruritus in HD patients is of variable severity, but mostly severe and disturbing sleep and daily activity.[@b14-ccid-7-313]--[@b16-ccid-7-313],[@b21-ccid-7-313],[@b22-ccid-7-313] Sultan et al[@b17-ccid-7-313] reported that pruritus was found in 55% of their HD patients. They concluded that HD patients have lower water content in the stratum corneum in addition to retention of middle molecules (B2 microglobulin, parathyroid hormone, and glycosylation end products), which are thought to cause pruritus. Others suggested that the cause of pruritus was due to increased serum histamine levels, which may be due to allergic sensitization to dialyzer membrane components and to impaired renal excretion of histamine or due to inadequate dialysis, anemia, peripheral neuropathy, and/or uremic toxins.[@b8-ccid-7-313],[@b23-ccid-7-313] In another study, pruritus began after starting HD in about 50% of the patients.[@b8-ccid-7-313] Several previous studies have reported that the serum parathormone level in HD patients with pruritus was significantly higher than in those without pruritus.[@b24-ccid-7-313]--[@b26-ccid-7-313] However, Ståhle-Bäckdahl et al[@b26-ccid-7-313] found no association between the severity of pruritus and the serum parathormone levels. On the contrary, other studies have reported the absence of significant association between pruritus and serum parathormone levels.[@b27-ccid-7-313]--[@b29-ccid-7-313]

Ecchymosis was found in 47.3% of patients in the current study; this may be explained by the use of heparin during dialysis. Peres et al[@b30-ccid-7-313] reported that ecchymosis was present in 60% of their patients on HD. They observed that easy bruisability and increased skin fragility were worse in the patients who were on dialysis for a longer time. On the other hand, Udayakumar et al[@b14-ccid-7-313] reported ecchymosis in only 9% of their HD patients; they attributed ecchymosis to defects in platelet function, use of heparin during dialysis, and increased vascular fragility.

As regards follicular hyperkeratosis, it was found in 48.4% of patients in the present study, mostly in females, and the most affected site was the lower limbs. While Sultan et al[@b17-ccid-7-313] reported that follicular hyperkeratosis was found only in 10% of their HD patients, they explained that this is due to increased keratinization of the skin. The difference could be attributed to the higher existence of xerosis in the patients in the present study.

More than 70% of the patients in the current study had hair changes. The results of the present study were in agreement with Mirza et al,[@b12-ccid-7-313] who reported that hair changes were present in 56.6% of their HD patients. Sultan et al[@b17-ccid-7-313] reported that hair changes were detected in 47% of their HD patients. Udayakumar et al[@b14-ccid-7-313] reported that 16% of their HD patients had lusterless hair, and they explained hair problems by presence of anemia, decreased sebum secretion, and secondary hyperparathyroidism. The higher existence of hair changes in the present study could be attributed to higher incidence of iron deficiency anemia, disturbed parathormone level, or psychic impacts of ESRD and dialysis with neglect of hair care.

The prevalence of half and half nails, a characteristic finding of chronic renal failure, was 76.3% in patients in the present study, compared to 1.4%[@b18-ccid-7-313] in the general population. Udayakumar et al,[@b14-ccid-7-313] Mirza et al,[@b12-ccid-7-313] and Sultan et al[@b17-ccid-7-313] found half and half nails were found in 21%, 36.75%, and 28% respectively, of their patients on HD.

Koilonychia was found in 23.7% of patients in the present study. This may be due to higher incidence of anemia in our patients. Koilonychia has been reported in 18%--93% of patients with ESRD in various studies.[@b14-ccid-7-313],[@b17-ccid-7-313] Subungal hyperkeratosis was found in 19.4% of HD patients in the present study, while onychomycosis was found in 30.1%. Hajheydari et al did not find any patients with fungal nail infection in their study,[@b8-ccid-7-313] while Naderi et al[@b15-ccid-7-313] reported onychomycosis in 1.9%.

Melanonychia was a common finding in our HD patients (24.7%). This can be attributed to deposition of melanin in the nail bed as a result of failure of the kidneys to excrete β-melanocyte stimulating hormone. Sultan et al[@b17-ccid-7-313] found brown nails in only 6% of their HD patients. The difference could be attributed to the different study populations and their tendency to pigmentation.

Mucosal disorders were very common in our study patients, and the high incidence of pallor among our patients is a reflection of the high rate of anemia among them. Thomas et al[@b31-ccid-7-313] have also reported that anemia was a common problem in their ESRD patients; 45.45% of them had pallor. Deficient erythropoietin production by the failing kidneys and dietary deficiencies of iron, folic acid, and vitamin B12 contribute to anemia.[@b32-ccid-7-313] Hajheydari et al[@b8-ccid-7-313] have reported a prevalence of mucosal lesions in 24% of their patients, with the most common finding being furred tongue (8%), while Yaghubi et al reported a prevalence of mucosal disorders in 29% of their patients, with gingivitis being the most common finding.[@b16-ccid-7-313]

Aphthous stomatitis was found in 10.7% of patients in the current study, which may be due to elevated blood urea level and bad oral hygiene. This finding is similar to the findings of Sultan et al,[@b17-ccid-7-313] who reported the presence of oral ulcers in 9% of their HD patients. On the other hand, Udayakumar et al[@b14-ccid-7-313] reported ulcerative stomatitis in 29% of their patients; this high incidence was attributed by the authors to the intake of alcohol, spices, hot food, and tobacco smoking, which are precipitating factors for ulcerative stomatitis.

Yellow sclera was found in 55.9% of the patients in the current study, which may be due to impaired liver function and hypercarotenemia.

Various other dermatoses, such as acquired perforating dermatoses, calcific uremic arteriopathy, bullous dermatoses of HD, nephrogenic fibrosing dermopathy, and arteriovenous shunt dermatitis, have been frequently reported in previous publications, but they were not detected in any of our studied HD patients, neither during the period of the study (6 months) nor in their past history.

There were nonsignificant correlations between the presence of mucocutaneous, hair, and nail changes and laboratory findings in HD patients in the present study. This could be attributed to the frequent changes and instability of these laboratory test results from time to time according to the circumstances (effect of dialysis sessions, meals, drugs, and other factors). However, there was a positive correlation between pruritus and serum parathormone level, and a negative correlation between mucous membrane changes and hemoglobin level.

In conclusion, we reported that nonspecific skin manifestations were very frequent in patients on HD; xerosis was the most frequent, followed by half and half nails, lusterless hair, brittle hair, hyperpigmentation, pallor of oral mucosa and yellow sclera, pruritus, follicular hyperkeratosis, ecchymosis, xerostomia, macroglossia, bleeding gums, onychomycosis, melanoychia, koilonychia, subungal hyperkeratosis, aphthous stomatitis, and Mees' lines. With the development of HD techniques, the life expectancy of uremic patients has increased, giving time for more and newer cutaneous changes to appear.

Based on the results of the current study, larger randomized studies are recommended to determine the accurate prevalence of cutaneous manifestations in patients on HD in Egypt. Patients on HD should apply emollients regularly, aiming to decrease xerosis and subsequent pruritus, and they should receive iron supplements to avoid anemia. In addition, patients on HD should avoid sunlight and apply sunscreens to avoid hyperpigmentation.
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![Dermatologic changes in patients on hemodialysis.\
**Notes:** (**A**) Xerosis on the leg. (**B**) Severe pruritus with scratch marks on lower limb. (**C**) Hyperpigmentation on the face. (**D**) Hyperpigmentation of the hands with melanonychia. (**E**) Ecchymosis. (**F**) Diffuse hair loss. (**G**) Half and half nails. (**H**) Koilonychia. (**I**) Onychomycosis.](ccid-7-313Fig1){#f1-ccid-7-313}

###### 

Prevalence of cutaneous changes in patients on hemodialysis

                               Patients (n=93)   
  ---------------------------- ----------------- -------
  Cutaneous changes                              
   Xerosis                     80                86
   Pruritus                                      
    Mild                       20                21.5
    Moderate                   20                21.5
    Severe                     8                 8.6
   Ecchymosis                  44                47.3
   Hyperpigmentation                             
    On exposed parts           33                35.5
    All over the body          19                20.4
   Follicular hyperkeratosis   45                48.4
  Hair changes                                   
   Brittle hair                63                67.7
   Lusterless hair             64                68.8
   Diffuse hair loss           6                 6.5
  Nail changes                                   
   Half and half nail          71                76.3
   Koilonychia                 22                23.7
   Subungal hyperkeratosis     18                19.4
   Melanonychia                23                24.7
   Onychomycosis               28                30.1
   Mees' line                  9                 9.7
  Mucous membrane changes                        
   Pallor                      52                55.9
   Xerostomia                  40                43.01
   Macroglossia                35                37.6
   Bleeding gum                33                35.4
   Aphthous stomatitis         10                10.7
   Scleral changes             52                55.9

###### 

Correlation between skin, hair, nail, and mucous membrane changes in patients on hemodialysis and duration of hemodialysis

                            Duration of hemodialysis   
  ------------------------- -------------------------- -------
  Skin manifestations       0.014                      0.225
  Hair changes              0.152                      0.390
  Nail changes              0.096                      0.523
  Mucous membrane changes   0.031                      0.224

###### 

Correlation between skin manifestations and hair, nail, and mucous membrane changes in patients on hemodialysis and their laboratory investigations

  Laboratory investigations          Skin manifestations   Hair changes                                       Nail changes   Mucous membrane changes                             
  ---------------------------------- --------------------- -------------------------------------------------- -------------- ------------------------- -------- ------- -------- --------------------------------------------------
  Complete blood count                                                                                                                                                           
   Hemoglobin level (gm/dL)          −0.339                0.011                                              −0.225         0.048                     −0.384   0.014   −0.415   0.001[\*](#tfn1-ccid-7-313){ref-type="table-fn"}
   Leukocytic count (cells/mm^3^)    0.110                 0.225                                              0.038          0.719                     0.198    0.057   0.064    0.220
   Platelet count (cells/mm^3^)      −0.115                0.225                                              −0.056         0.594                     −0.821   0.436   −0.123   0.142
  Renal function tests                                                                                                                                                           
   Blood urea nitrogen (mg/dL)       0.109                 0.209                                              0.196          0.158                     0.241    0.247   0.225    0.269
   Creatinine (mg/dL)                0.062                 0.582                                              0.087          0.407                     0.115    0.633   0.118    0.774
  Serum electrolytes                                                                                                                                                             
   Ca^++^ (mmol/L)                   −0.075                0.896                                              −0.054         0.606                     −0.080   0.852   −0.027   0.441
   P^3−^ (mmol/L)                    0.133                 0.556                                              0.146          0.164                     0.028    0.411   0.030    0.777
   Na^+^ (mmol/L)                    0.080                 0.147                                              0.023          0.524                     0.243    0.019   0.007    0.945
   K^+^ (mmol/L)                     0.027                 0.528                                              0.140          0.182                     0.006    0.956   0.136    0.201
  Parathormone (pg/mL)               0.441                 0.010[\*](#tfn1-ccid-7-313){ref-type="table-fn"}   0.219          0.052                     0.045    0.668   0.010    0.953
  Serum alkaline phosphatase (U/L)   0.029                 0.983                                              0.144          0.558                     0.039    0.523   0.075    0.741

**Notes:**

Statistically significant.
